For most ROP infants, anti-VEGF drugs could effectively improve the structural outcomes in no shorter than 6-month follow-up period although some recurrences may occur in 2.8%–35.7% of them [9–13]. The gene discussed is VEGFA; the disease is retinopathy of prematurity.